Poseida Therapeutics, Inc.

DB:2RZ Stock Report

Market Cap: €219.4m

Poseida Therapeutics Valuation

Is 2RZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2RZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2RZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2RZ's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2RZ?

Other financial metrics that can be useful for relative valuation.

2RZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1x
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 2RZ's PS Ratio compare to its peers?

The above table shows the PS ratio for 2RZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.1x
HPHA Heidelberg Pharma
12.5x13.4%€118.8m
FYB Formycon
14.7x32.5%€893.4m
2INV 2invest
7.7xn/a€59.8m
BIO3 Biotest
1.4x-4.1%€1.4b
2RZ Poseida Therapeutics
2.7x23.1%€239.9m

Price-To-Sales vs Peers: 2RZ is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (9.1x).


Price to Earnings Ratio vs Industry

How does 2RZ's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 2RZ is good value based on its Price-To-Sales Ratio (2.7x) compared to the European Biotechs industry average (9x).


Price to Sales Ratio vs Fair Ratio

What is 2RZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2RZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.7x
Fair PS Ratio1.3x

Price-To-Sales vs Fair Ratio: 2RZ is expensive based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2RZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.25
€12.54
+457.8%
30.9%€17.91€8.96n/a3
Oct ’25€2.53
€12.54
+394.8%
30.9%€17.91€8.96n/a3
Sep ’25€2.47
€12.81
+418.3%
30.9%€18.30€9.15n/a3
Aug ’25€2.99
€12.91
+332.2%
30.9%€18.44€9.22n/a3
Jul ’25€2.64
€12.94
+390.4%
30.9%€18.48€9.24n/a3
Jun ’25€2.59
€12.94
+399.5%
30.9%€18.48€9.24n/a3
May ’25€2.10
€13.14
+527.1%
30.9%€18.78€9.39n/a3
Apr ’25€2.90
€12.80
+341.4%
30.9%€18.29€9.14n/a3
Mar ’25€3.60
€12.88
+257.7%
30.9%€18.40€9.20n/a3
Feb ’25€3.08
€12.88
+318.1%
30.9%€18.40€9.20n/a3
Jan ’25€3.10
€12.71
+310.1%
30.9%€18.16€9.08n/a3
Dec ’24€2.42
€11.26
+365.3%
21.9%€13.79€7.35n/a4
Nov ’24€1.88
€11.55
+514.5%
21.9%€14.15€7.54n/a4
Oct ’24€2.28
€11.59
+408.2%
21.9%€14.19€7.57€2.534
Sep ’24€1.89
€10.75
+468.8%
21.7%€13.67€7.29€2.475
Aug ’24€1.55
€12.35
+696.6%
19.2%€15.66€9.21€2.995
Jul ’24€1.50
€12.35
+723.1%
19.2%€15.66€9.21€2.645
Jun ’24€2.10
€12.35
+487.9%
19.2%€15.66€9.21€2.595
May ’24€2.16
€12.59
+483.0%
19.2%€15.98€9.40€2.105
Apr ’24€2.82
€12.59
+346.6%
19.2%€15.98€9.40€2.905
Mar ’24€5.30
€14.03
+164.7%
33.5%€22.75€9.48€3.605
Feb ’24€5.70
€13.95
+144.8%
33.5%€22.63€9.43€3.085
Jan ’24€4.82
€14.24
+195.4%
37.6%€23.17€9.65€3.104
Dec ’23€4.30
€14.24
+231.2%
37.6%€23.17€9.65€2.424
Nov ’23€4.04
€16.32
+303.9%
32.5%€23.38€10.72€1.884
Oct ’23€3.26
€16.32
+400.5%
32.5%€23.38€10.72€2.284

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies